pembrolizumab
Merck
[]
pleasure to present at esmo. immunotherapy offers the opportunity for long term survival in hnscc. oncology evolves for the benefit of patients #esmo2022 
Hematologist and Medical Oncologist, CHUM, Professor of Medicine, Université de Montréal, Scientist, Citizen, Runner